Scott Neils - Xtant Medical Chief Officer
| XTNT Stock | USD 0.36 0.01 2.86% |
Insider
Scott Neils is Chief Officer of Xtant Medical Holdings
| Age | 40 |
| Address | 664 Cruiser Lane, Belgrade, MT, United States, 59714 |
| Phone | 406 388 0480 |
| Web | https://www.xtantmedical.com |
Scott Neils Latest Insider Activity
Tracking and analyzing the buying and selling activities of Scott Neils against Xtant Medical stock is an integral part of due diligence when investing in Xtant Medical. Scott Neils insider activity provides valuable insight into whether Xtant Medical is net buyers or sellers over its current business cycle. Note, Xtant Medical insiders must abide by specific rules, including filing SEC forms every time they buy or sell Xtant Medical'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Scott Neils over six months ago Acquisition by Scott Neils of 177551 shares of Xtant Medical subject to Rule 16b-3 |
Xtant Medical Management Efficiency
The company has return on total asset (ROA) of (0.1058) % which means that it has lost $0.1058 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0877) %, meaning that it created substantial loss on money invested by shareholders. Xtant Medical's management efficiency ratios could be used to measure how well Xtant Medical manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Xtant Medical's Return On Tangible Assets are comparatively stable compared to the past year. Return On Assets is likely to gain to 0.01 in 2024, whereas Return On Capital Employed is likely to drop (0.15) in 2024. Change To Liabilities is likely to gain to about 1.9 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 16 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Craig MD | Guardant Health | 57 | |
| Priscilla Hung | Veeva Systems Class | 53 | |
| Justin Steinman | Definitive Healthcare Corp | N/A | |
| Amy Summy | Laboratory of | 58 | |
| David Kronfeld | Definitive Healthcare Corp | N/A | |
| MPH MD | Laboratory of | 48 | |
| Jim Rivas | Doximity | N/A | |
| William Roper | Cigna Corp | 71 | |
| Pinal Patel | Veeva Systems Class | N/A | |
| Mary Moore | Mednax Inc | 64 | |
| Kumud Kalia | Guardant Health | 58 | |
| Nate Gross | Doximity | N/A | |
| Michael Rucker | Mednax Inc | 51 | |
| Perry Gold | Doximity | N/A | |
| Paul MD | Laboratory of | 62 | |
| Paul Sanford | Cigna Corp | 56 | |
| D Gilliland | Laboratory of | 66 | |
| Andy Ament | Guardant Health | N/A | |
| Elder Granger | Cigna Corp | 67 | |
| Michelle Abelson | Laboratory of | N/A | |
| Neesha Hathi | Cigna Corp | 47 | |
Management Performance
| Return On Equity | -0.0877 | ||||
| Return On Asset | -0.11 |
Xtant Medical Holdings Leadership Team
Elected by the shareholders, the Xtant Medical's board of directors comprises two types of representatives: Xtant Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Xtant. The board's role is to monitor Xtant Medical's management team and ensure that shareholders' interests are well served. Xtant Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Xtant Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sean Browne, CEO President | ||
| Scott Neils, Chief Officer | ||
| Kevin Brandt, Senior Vice President Chief Commercial Officer | ||
| Kevin ODare, VP US | ||
| Catherine Lundy, Vice Resources | ||
| Mark Schallenberger, Chief Officer |
Xtant Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Xtant Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0877 | ||||
| Return On Asset | -0.11 | ||||
| Profit Margin | (0.03) % | ||||
| Operating Margin | (0.1) % | ||||
| Current Valuation | 79.4 M | ||||
| Shares Outstanding | 139.01 M | ||||
| Shares Owned By Insiders | 7.83 % | ||||
| Shares Owned By Institutions | 65.12 % | ||||
| Number Of Shares Shorted | 197.47 K | ||||
| Price To Earning | (0.41) X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Xtant Stock Analysis
When running Xtant Medical's price analysis, check to measure Xtant Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xtant Medical is operating at the current time. Most of Xtant Medical's value examination focuses on studying past and present price action to predict the probability of Xtant Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xtant Medical's price. Additionally, you may evaluate how the addition of Xtant Medical to your portfolios can decrease your overall portfolio volatility.